Mini
That is great news and thanks for sharing your reserch and bringing it to this forum.
Up untill now there has been a lot of posts on this forum questioning the logic of using chemo in these trials with Her-Vax in the fear that the chemo would undo the immune systems response and produce sub-optimal results, Its good to see from the trial data review at
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216745/ concludes that problems are unlikely, so should help put to rest concerns investors may have around the use of Her-Vaxx and chemo in the currant trials
It is also really good to see that IMU management (but then would else would you expect these people are amonst those whom are at top of their field ) must have already taken into account that Cisplatin would probably make a good match for Her-Vaxx.
Its probably another box ticked
FP
Add to My Watchlist
What is My Watchlist?
